AsthmaSymb NISNCT00532922
A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®
An observational study of Asthma, run by AstraZeneca at 19 sites in China.
Trial summary
The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance. Read more about this study
- Who is it for?
- Ages 6 years and older
- Conditions the study is for
- Asthma
- How many people
- 310 participants
- Where
- 19 sitesChina
- Study dates
- Apr 2007to Nov 2007
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Natural History, longitudinal, defined population
Who may be able to join
- Provision of informed consent
- Asthmatics who has been prescribed Symbicort according to physician's judgement
- Usage of Symbicort should follow local prescribing information
Who cannot join
- Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
- No previous enrolment in the present study
Trial locations and contacts
19 sites in 1 country.
19 sites in 1 country
China19 sites
Research Site
Beijing
Research Site
Chengdu, Sichuan
Research Site
Chongqing
Research Site
Fuzhou, Fujian
Research Site
Guangzhou, Guangdong
Research Site
Hangzhou
Research Site
Hefel, Anhui
Research Site
Nanjong, Jiangsu
Research Site
Qingdao, Shandong
Research Site
Shanghai
Research Site
Shenyand, Liaoning
Research Site
Shenzhen, Guangdong
Research Site
Suzhou, Jiangsu
Research Site
Taiyuan, Shanxi
Research Site
Wenzhou, Zhejiang
Research Site
Wuhan, Hubei
Research Site
Wuhan, Hubel
Research Site
Xi’an, Shanxi
Research Site
Zhengzhou, Henan
About this study
The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.
- Conditions
- Asthma
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Chinese asthma patient prescribed Symbicort® Turbuhaler® |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2007 (estimated)
- Study startApr 2007
- Study completionNov 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AsthmaStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 310 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Zhou Xin, Principal investigator, Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineHong Jianguo, Principal investigator, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00532922
- Sponsor's protocol ID
- NIS-RCN-SYM-2006/1
- Acronym
- Symb NIS
- Status last verified
- Jun 2009
- First submitted
- 20 Sep 2007
- Last updated
- 9 Jun 2009
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Jun 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®
- ClinicalTrials.gov ID
- NCT00532922
- Acronym / sponsor ID
- Symb NIS / NIS-RCN-SYM-2006/1
- Conditions
- Asthma
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 310 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Apr 2007
- Study completion
- Nov 2007 (actual)
- First posted
- 21 Sep 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 1 | – | –Chinese asthma patient prescribed Symbicort® Turbuhaler® |
Who may qualify
- Ages
- 6 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Natural History, longitudinal, defined population
Key inclusion criteria (3 listed)
- Provision of informed consent
- Asthmatics who has been prescribed Symbicort according to physician's judgement
- Usage of Symbicort should follow local prescribing information
Key exclusion criteria (2 listed)
- Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
- No previous enrolment in the present study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jun 2009.
Related trials for Asthma
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zhou Xin principal investigator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hong Jianguo principal investigator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
19 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Asthma, run by AstraZeneca at 19 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jun 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 19 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2009.